Search results for "antico"

showing 10 items of 736 documents

Clinical course of patients with symptomatic isolated superficial vein thrombosis: the ICARO follow‐up study

2017

Essentials Late sequelae of isolated superficial vein thrombosis (iSVT) have rarely been investigated. We studied 411 consecutive outpatients with acute iSVT with a median follow-up of three years. Male sex and cancer are risk factors for future deep vein thrombosis or pulmonary embolism. Patients without cancer appear to be at a negligible risk for death. SUMMARY Background Studies of long-term thromboembolic complications and death following acute isolated superficial vein thrombosis (iSVT) of the lower extremities are scarce. Objectives To investigate the course of iSVT in the setting of an observational multicenter study. Methods We collected longitudinal data of 411 consecutive outpati…

MaleTime FactorsSuperficial vein thrombosisDeep veinKaplan-Meier Estimate030204 cardiovascular system & hematology0302 clinical medicineRecurrenceRisk FactorsInterquartile rangecohort study; death; major bleeding; superficial vein thrombosis; venous thromboembolism; Adult; Aged; Anticoagulants; Cause of Death; Female; Hemorrhage; Humans; Incidence; Italy; Kaplan-Meier Estimate; Longitudinal Studies; Lower Extremity; Male; Middle Aged; Multivariate Analysis; Neoplasms; Odds Ratio; Proportional Hazards Models; Pulmonary Embolism; Recurrence; Retrospective Studies; Risk Factors; Sex Factors; Time Factors; Treatment Outcome; Venous ThrombosisCause of DeathNeoplasmssuperficial vein thrombosiOdds RatioLongitudinal StudiesCause of deathVenous ThrombosisIncidenceAnticoagulantHematologyMiddle AgedThrombosisPulmonary embolismVenous thrombosisTreatment Outcomemedicine.anatomical_structureItalyLower Extremity030220 oncology & carcinogenesisFemaleAdultmedicine.medical_specialtymedicine.drug_classvenous thromboembolismHemorrhage03 medical and health sciencesSex FactorsdeathInternal medicinesuperficial vein thrombosiscohort studymedicineHumansAgedProportional Hazards ModelsRetrospective Studiesbusiness.industryAnticoagulantsmedicine.diseaseSurgerymajor bleedingMultivariate AnalysisPulmonary Embolismbusinesscohort study; death; major bleeding; superficial vein thrombosis; venous thromboembolism; HematologyJournal of Thrombosis and Haemostasis
researchProduct

Stereoselective drug distribution and anticoagulant potency of the enantiomers of phenprocoumon in rats

1977

Abstract The elimination, distribution and anticoagulant activity of S(—)-, R(+)-, and R,S(±)-phenprocoumon were determined in male Wistar-Lewis rats after intravenous injection of a single dose of 0·6 mg kg−1. From the plasma concentrations which elicited the same anticoagulant effect, S(—)-phenprocoumon was 4 to 5 times more potent than R(+)-phenprocoumon. The potency of the racemate was between those of the enantiomers. The mean biologic half-life of the S(—)-enantiomer was shorter (12·5 h) than that of R(+)-phenprocoumon (17·8 h). No differences were observed in the apparent volume of distribution. However, the mean liver: plasma concentration ratio was higher for the S(—)-(6·9) than fo…

MaleTime Factorsmedicine.drug_classPharmaceutical ScienceIn Vitro TechniquesPharmacologyPhenprocoumonPharmacokineticsmedicineAnimalsPotencyDistribution (pharmacology)PharmacologyVolume of distributionChemistryAnticoagulantAnticoagulantsRats Inbred StrainsStereoisomerism4-HydroxycoumarinsBlood ProteinsRatsKineticsLiverPhenprocoumonStereoselectivityBlood Coagulation TestsEnantiomerProtein Bindingmedicine.drugJournal of Pharmacy and Pharmacology
researchProduct

Antiepileptic effect of dimethyl sulfoxide in a rat model of temporal lobe epilepsy.

2012

Dimethyl sulfoxide (DMSO) is an amphipathic molecule widely used to solubilize water-insoluble compounds. In many studies it was reported that DMSO is capable of affecting several biological processes, thus resulting in a potential cause for the misinterpretation of experimental data. Recent papers showed that DMSO modified the brain bioelectric activity in animal models of epilepsy. In an in vivo model of temporal lobe epilepsy in the rat, we examined the effects of different doses (10%, 50% and 100%) of DMSO on the maximal dentate activation (MDA). The results show that DMSO induced a dose-dependent significant reduction of the electrically induced paroxysmal activity.

MaleTreatment outcomeRat modelAction PotentialsPharmacologySettore BIO/09 - FisiologiaTemporal lobeEpilepsychemistry.chemical_compoundIn vivomedicineAnimalsHumansDimethyl SulfoxideRats WistarTemporal lobe epilepsyDose-Response Relationship DrugChemistryDimethyl sulfoxideGeneral Neurosciencemedicine.diseaseRatsDose–response relationshipDisease Models AnimalMaximal dentate activationTreatment OutcomeBiochemistryCerebellar NucleiEpilepsy Temporal LobeSolubilizationAnticonvulsantsNeuroscience letters
researchProduct

Outcomes of cataract surgery in diabetic patients: results of the Pan American Collaborative Retina Study Group.

2014

Purpose: This study was designed to evaluate the visual and anatomical outcomes after cataract surgery in diabetic patients with different intraoperative therapeutic strategies. Methods: The research design comprised of a multicentric, retrospective, interventional study conducted at 6 centers in Argentina, Brazil, Costa Rica, Puerto Rico, Spain, and Venezuela. We included 138 diabetic patients with at least 6-month follow-up following phacoemulsification and intraocular lens implantation. Best-corrected visual acuity (BCVA) and central subfield thickness were collected at baseline and at 1-, 2-, 3-, and 6-month follow-up. Of these, 42 cases were not treated with any intraoperative coadjuva…

MaleVascular Endothelial Growth Factor ATriamcinolone acetonideVisual acuitygenetic structuresmedicine.medical_treatmentExtração de catarataVisual AcuityIntraocular lensCuidados intraoperatóriosAngiogenesis InhibitorsTriamcinolonelcsh:OphthalmologyLens Implantation IntraocularDiabetic retinopathyAntibodies monoclonalAged 80 and overGeneral MedicineDiabetic retinopathyMiddle AgedMulticenter studyBevacizumabTreatment OutcomeCataract extractionChemotherapy AdjuvantEstudo multicêntricoIntravitreal InjectionsFemalemedicine.symptommedicine.drugAdultmedicine.medical_specialtyBevacizumabAntibodies Monoclonal HumanizedCataractMacular EdemaIntraoperative careOphthalmologyEdema macularmedicineAnticorpos monoclonaisHumansMacular edemaGlucocorticoidsAgedRetrospective StudiesMacular edemaDiabetic RetinopathyIntraoperative CarePhacoemulsificationbusiness.industryRetinopatia diabéticaPhacoemulsificationCataract surgeryFacoemulsificaçãomedicine.diseaseSurgeryImplante de lente intraocularOphthalmologyLens implantation intraocularlcsh:RE1-994businessFollow-Up StudiesArquivos brasileiros de oftalmologia
researchProduct

Choice of New Oral Anticoagulant Agents Versus Vitamin K Antagonists in Atrial Fibrillation: FANTASIIA Study.

2015

Introduction: Atrial fibrillation (AF) is associated with an increased risk of thromboembolic events. Many patients with AF receive chronic anticoagulation, either with vitamin K antagonists (VKAs) or with non-VKA oral anticoagulants (NOACs). We sought to analyze variables associated with prescription of NOAC. Methods: Patients with AF under anticoagulation treatment were prospectively recruited in this observational registry. The sample comprised 1290 patients under chronic anticoagulation for AF, 994 received VKA (77.1%) and 296 NOAC (22.9%). Univariate and multivariate analyses were performed to identify variables associated with use of NOAC. Results: Mean age was 73.8 ± 9.4 years, and 4…

MaleVitamin KClinical Decision-MakingMEDLINEAdministration OralHemorrhage030204 cardiovascular system & hematologyVitamin kanticoagulant treatment03 medical and health sciences0302 clinical medicineClinical decision makingFibrinolytic AgentsAtrial FibrillationmedicineHumansPharmacology (medical)030212 general & internal medicineAgedPharmacologyAged 80 and overbusiness.industrynonvitamin K antagonist oral anticoagulantsAnticoagulantsAtrial fibrillationMiddle Agedmedicine.diseasevitamin K antagonistsIncreased riskAnticoagulant therapyAnesthesiaOral anticoagulantFemaleCardiology and Cardiovascular Medicinebusiness
researchProduct

Antithrombotic Therapy in Patients with Atrial Fibrillation and Acute Coronary Syndrome Treated Medically or with Percutaneous Coronary Intervention …

2019

Background: The safety and efficacy of antithrombotic regimens may differ between patients with atrial fibrillation who have acute coronary syndromes (ACS), treated medically or with percutaneous coronary intervention (PCI), and those undergoing elective PCI. Methods: Using a 2×2 factorial design, we compared apixaban with vitamin K antagonists and aspirin with placebo in patients with atrial fibrillation who had ACS or were undergoing PCI and were receiving a P2Y 12 inhibitor. We explored bleeding, death and hospitalization, as well as death and ischemic events, by antithrombotic strategy in 3 prespecified subgroups: patients with ACS treated medically, patients with ACS treated with PCI,…

MaleVitamin Kmedicine.medical_treatment030204 cardiovascular system & hematology0302 clinical medicineAntithromboticAtrial Fibrillation//purl.org/pe-repo/ocde/ford#3.02.04 [https]030212 general & internal medicineProspective Studies610 Medicine & healthAspirinVKADisease ManagementAtrial fibrillationVitamin K antagonistMiddle AgedCombined Modality TherapyHospitalizationTreatment Outcomesurgical procedures operativeElective Surgical ProceduresCardiologyApixabanDrug Therapy CombinationFemaleCardiology and Cardiovascular Medicinemedicine.drugmedicine.medical_specialtyAcute coronary syndromemedicine.drug_classPyridonesDOACHemorrhageP2Y12 inhibitor03 medical and health sciencesPercutaneous Coronary InterventionFibrinolytic AgentsPhysiology (medical)Internal medicinemedicineHumanscardiovascular diseasesAcute Coronary SyndromeAgedProportional Hazards ModelsAspirinbusiness.industryPercutaneous coronary interventionAnticoagulantsCardiovascular Agentsmedicine.diseaseConventional PCIPurinergic P2Y Receptor AntagonistsPyrazolesbusinessPlatelet Aggregation Inhibitors
researchProduct

Perioperative risk of bleeding with antithrombotic agents in macular surgery: a national, prospective, multicentre study

2020

International audience; Purpose To compare the risk of haemorrhagic complications in elective macular surgery between patients with no antithrombotic (AT) treatment (defined as patients with no history of AT therapy or who discontinued AT therapy) and patients who continued AT treatment during the surgery. Methods E-case report forms were prospectively recorded in a database before vitreoretinal surgery and 1 month after. Data on patient characteristics, surgical techniques, haemorrhagic complications and antithrombotic status were collected. Patients with retinal detachment, proliferative diabetic retinopathy and previous retinal haemorrhage were excluded. Results A total of 748 procedures…

Male[SDV]Life Sciences [q-bio]030204 cardiovascular system & hematologynoncardiac surgeryantiplateletsurgery0302 clinical medicineRisk FactorsAntithromboticMedicineProspective Studiesoral anticoagulantsguidelinesantithrombotic agenteducation.field_of_studyAnticoagulantvitreoretinalRetinal HemorrhageGeneral MedicineDiabetic retinopathy3. Good healthPopulation SurveillanceFemalemacular surgeryhaemorrhagehemorrhagemanagementmedicine.medical_specialtymedicine.drug_classPopulationPostoperative Hemorrhagemaintenance03 medical and health sciencesHumans[SDV.MHEP.OS]Life Sciences [q-bio]/Human health and pathology/Sensory OrganseducationAgedbusiness.industryanticoagulantAnticoagulantsPerioperativeOdds ratioRetinal Perforationsmedicine.diseasedual antiplatelet therapyvitreoretinal surgeryConfidence intervalSurgerywarfarinOphthalmology030221 ophthalmology & optometrybusiness[SDV.MHEP]Life Sciences [q-bio]/Human health and pathologyFollow-Up StudiesRetinal haemorrhage
researchProduct

Dosing issues with non-vitamin K antagonist oral anticoagulants for the treatment of non-valvular atrial fibrillation: Why we should not underdose ou…

2018

Summary Non-vitamin K antagonist oral anticoagulants (NOACs) – dabigatran, rivaroxaban, apixaban and edoxaban – are well established in terms of preventing stroke or systemic embolism in patients with non-valvular atrial fibrillation and high thromboembolism risk. When prescribed incorrectly, NOACs are associated with an increased risk of ischaemic events and bleeding. Current NOAC labels explicitly address dose adjustments according to age, body weight, renal function and concomitant treatment with P-glycoprotein inhibitors. The required dose adjustments vary significantly from molecule to molecule, thereby creating a complex dose adjustment environment. Furthermore, recommendations suppor…

Male[SDV]Life Sciences [q-bio]Administration Oral030204 cardiovascular system & hematologychemistry.chemical_compound0302 clinical medicineRisk FactorsEdoxabanAtrial FibrillationDrug Dosage Calculations030212 general & internal medicineStrokeComputingMilieux_MISCELLANEOUSAged 80 and over[SDV.MHEP] Life Sciences [q-bio]/Human health and pathologyAtrial fibrillationGeneral MedicineMiddle AgedVitamin K antagonist[SDV.MHEP.CSC] Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system3. Good healthStroke[SDV] Life Sciences [q-bio]Treatment OutcomeAnesthesiaFemaleApixabanCardiology and Cardiovascular Medicinemedicine.drugmedicine.medical_specialtymedicine.drug_classClinical Decision-MakingHemorrhageDabigatran03 medical and health sciences[SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemmedicineHumansIntensive care medicineBlood CoagulationAgedHAS-BLEDRivaroxabanDose-Response Relationship Drugbusiness.industryPatient SelectionAnticoagulantsmedicine.diseasechemistrybusiness[SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
researchProduct

Inhibitory effects of N-valproyl-L-tryptophan on high potassium, low calcium and low magnesium-induced CA1 hippocampal epileptiform bursting activity…

2012

N-valproyl-l-tryptophan (VPA-Tryp), new antiepileptic drug, was tested on CA1 hippocampal epileptiform bursting activity obtained by increasing potassium and lowering calcium and magnesium concentrations in the fluid perfusing rat brain slices. Each slice was treated with a single concentration (0.2, 0.5, 1 or 2 mM) of Valproate (VPA) or VPA-Tryp. Both burst duration and interburst frequency during and after treatment were off-line compared with baseline values. For both parameters, the latency and the length of statistically significant response periods as well as the magnitude of drug-induced responses were calculated. VPA-Tryp evoked fewer and weaker early excitatory effects than VPA on …

Maleantiepileptic drug valproic acidPotassiumchemistry.chemical_elementAction PotentialsCalciumHippocampal formationPharmacologyIn Vitro TechniquesInhibitory postsynaptic potentialSettore BIO/09 - Fisiologiaamino-acidic derivativeBurstingmedicineReaction Timehippocampal epilepsyAnimalsDrug InteractionsMagnesiumRats WistarCA1 Region HippocampalBiological PsychiatryValproic AcidAnalysis of VarianceDose-Response Relationship DrugMagnesiumDipeptidesElectric StimulationRatsPsychiatry and Mental healthNeurologychemistrySettore CHIM/09 - Farmaceutico Tecnologico ApplicativoExcitatory postsynaptic potentialPotassiuminterictal burstslipids (amino acids peptides and proteins)AnticonvulsantsNeurology (clinical)medicine.drugJournal of neural transmission (Vienna, Austria : 1996)
researchProduct

International Normalized Ratio and Mortality Risk in Acute Heart Failure and Nonvalvular Atrial Fibrillation Patients Receiving Vitamin K Antagonists

2019

Introduction and objectives: Heart failure patients with nonvalvular atrial fibrillation (NVAF) on treatment with vitamin K antagonists (VKA) often have suboptimal international normalized ratio (INR) values. Our aim was to evaluate the association between INR values at admission due to acute heart failure and mortality risk during follow-up. Methods: In this observational study, we retrospectively assessed INR on admission in 1137 consecutive patients with acute heart failure and NVAF who were receiving VKA treatment. INR was categorized into optimal values (INR = 2-3, n = 210), subtherapeutic (INR 3, n = 267). Because INR did not meet the proportional hazards assumption for mortality, res…

Maleendocrine systemmedicine.medical_specialtyTime FactorsVitamin KHeart failure030204 cardiovascular system & hematologyVitamin kRisk Assessment03 medical and health sciences0302 clinical medicineRisk FactorsInterquartile rangeCause of DeathThromboembolismhealth services administrationMean Survival TimeInternal medicineAtrial FibrillationmedicineHumansheterocyclic compoundsInternational Normalized Ratiocardiovascular diseasesInternational normalized ratioNormal rangeAgedRetrospective StudiesHeart Failurebusiness.industryIncidencefungiAnticoagulantsAtrial fibrillationGeneral MedicinePrognosismedicine.diseaseAtrial fibrillationSurvival RateSpainHeart failureAcute DiseaseCardiologyFemaleObservational studybusinessFollow-Up StudiesRevista Española de Cardiología (English Edition)
researchProduct